Insmed’s TPIP Extension Study Completion: What Long-Term PH-ILD Data Could Mean for INSM Investors

Insmed (INSM) announced an update on their ongoing clinical study.

Insmed Inc. is running an extension study called “An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease.” The main goal is to track long-term safety and day-to-day use in people with this serious lung condition, which could support broader use if results stay positive.

The study tests Treprostinil Palmitil Inhalation Powder (TPIP), an inhaled drug delivered via a dry powder inhaler. It is designed to widen lung blood vessels and ease strain on the heart, aiming to improve breathing and exercise capacity in patients with pulmonary hypertension tied to interstitial lung disease.

The trial is interventional and open-label, meaning all participants know they receive active treatment rather than being blinded. There is a single treatment arm, so everyone gets TPIP under one plan, with the core purpose being treatment rather than comparison against another active medicine.

Participants either start TPIP once daily over a 3-week dose increase phase or transition directly from earlier TPIP trials. The overall treatment period runs up to 24 months, giving investors a look at how the drug behaves over longer, more real-world use, which is key for regulators and payers.

The study began after submission in December 2022, building on prior trials in the same patient group. The most recent update was filed on April 20, 2026, signaling that the clinical program remains active and the company is keeping regulators and investors informed.

The status is listed as completed, which suggests main follow-up is done and data collection is wrapping up. The lack of posted results so far means investors are still waiting on clarity around long-term safety and durability, a key swing factor for valuation.

For investors, this update matters because TPIP targets a high-need niche where few options exist, so positive long-term data could support premium pricing and stronger adoption. Insmed’s broader pipeline focus also means a successful PH-ILD program could diversify revenue beyond its current core assets.

Competing players in pulmonary hypertension, such as those marketing existing treprostinil products, will watch closely, as a convenient once-daily inhaled option could shift share in certain patient segments. Near term, the “completed” status may support sentiment, but the real stock driver will be the eventual readout and how it compares with current standard treatments.

Overall, the extension study of TPIP for PH-ILD is now completed and recently updated, with more detailed information and future announcements expected through the ClinicalTrials portal.

To learn more about INSM’s potential, visit the Insmed drug pipeline page.